Glycopryl F Inhaler: Your Premier PCD Pharma Franchise in Pulmonology

About Glycopyrrolate + Formoterol: A Dual-Action Therapy for COPD

Tapping into the High-Value Market of Chronic Respiratory Disorders

Why Glycopryl F Inhaler is a High-Profit Opportunity for Distributors

Partnering for Success with a Quality-Assured Product
Join Our Pharma Franchise for Unmatched Business Support

Home/Products /glycopyrrolate-9-mcg-formoterol-fumarate-4-8-mcg-inhaler

About the Product

Description


Glycopryl F Inhaler is an advanced and highly effective medication that combines two powerful bronchodilators to provide superior long-term management for Chronic Obstructive Pulmonary Disease (COPD). Each inhalation delivers a precise dose of Glycopyrrolate (9 mcg), a long-acting muscarinic antagonist (LAMA), and Formoterol Fumarate (4.8 mcg), a long-acting beta-2 agonist (LABA). This synergistic LAMA-LABA combination works by relaxing and widening the airways through two distinct mechanisms, offering more effective and sustained bronchodilation than single-agent therapies. This crucial dual action helps to improve lung function, ease breathing, and significantly reduce the frequency and severity of COPD exacerbations.

The respiratory segment of the Indian pharmaceutical market is a high-value, high-growth sector with a consistently high demand. The rising prevalence of chronic respiratory diseases, fueled by factors such as air pollution and smoking, ensures a continuous need for advanced maintenance therapies. Products like Glycopryl F Inhaler represent a premium category in the pulmonology segment, with a stable prescription base from specialists. This makes it a strategic choice for any distributor seeking a stable and profitable business, as its essential nature for long-term chronic disease management guarantees a steady and predictable revenue stream.

We are dedicated to empowering our franchise partners with all the tools necessary for success. Our product, manufactured in a WHO-GMP certified facility, ensures impeccable quality, efficacy, and safety, which is crucial for building trust with healthcare professionals and patients. We provide a complete promotional and marketing kit, including visual aids and product literature, to support your sales efforts. Our robust supply chain guarantees timely delivery and continuous stock availability, preventing any business interruptions. Partner with us to enter this stable and highly profitable market and establish a reputable and successful business as a key supplier of this top-quality respiratory medicine.

May include hoarseness, throat irritation, dry mouth, or cough. Long-term use can rarely lead to oral thrush (fungal infection). Rinse mouth after each use to prevent this.

Persistent asthma (mild to severe) Chronic obstructive pulmonary disease (COPD) Allergic and non-allergic airway inflammation Nebulization therapy in children and adults as prescribed

Use only with a nebulizer under medical supervision. Not for acute asthma attacks – use a rescue inhaler for quick relief. Rinse mouth after inhalation to prevent infections. Regular use is important for effectiveness – do not skip doses. Do not stop suddenly without consulting your doctor.

Store below 25°C. Protect from light and moisture. Do not freeze. Keep out of reach of children. Use immediately after opening the respule.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Glycopyrrolate 9 mcg + Formoterol Fumarate 4.8 mcg Inhaler in the PCD pharma franchise market?

This inhaler has strong demand in the respiratory and pulmonary care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on asthma, COPD, and chronic airway disease portfolios.

Why should medical distributors include this inhaler in their product range?

Medical distributors and agencies can benefit from consistent demand for management of Chronic Obstructive Pulmonary Disease (COPD), asthma, and long-term bronchospasm control. Glycopyrrolate (9 mcg) acts as a long-acting muscarinic antagonist (LAMA) that relaxes airway muscles Formoterol fumarate (4.8 mcg) is a long-acting beta-agonist (LABA) that improves airflow and reduces breathing difficulty This dual bronchodilator combination supports effective long-term respiratory care.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this inhaler?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Glycopyrrolate + Formoterol Inhaler with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from strong pulmonologist prescriptions, high COPD patient demand, chronic daily usage, hospital and clinic supply opportunities, reliable supply chain support, and good margins in respiratory medicines.

How can I become a distributor or franchise partner for this inhaler?

Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.